Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Drug shortages in the UK have more than doubled between 2020 and 2023, a recent study by the Nuffield Trust reveals. Brexit is cited as a significant factor exacerbating the country's struggle to manage shortages in medicine supplies.
納菲爾德信託基金最近的一項研究顯示，在2020年至2023年之間，英國的藥品短缺增加了一倍以上。英國脫歐被認爲是加劇該國管理藥品供應短缺的重要因素。
Since the UK departed from the European Union in January 2020, the nation has grappled with persistently heightened shortages, particularly concerning crucial treatments like antibiotics and epilepsy drugs.
自英國於2020年1月退出歐盟以來，英國一直在努力應對持續加劇的短缺，特別是在抗生素和癲癇藥物等關鍵治療方面。
The research highlights a substantial increase in warnings issued by drug companies regarding impending shortages.
該研究突出表明，製藥公司就即將出現的短缺發出的警告大幅增加。
In 2023 alone, there were 1,643 warnings compared to 648 in 2020. Consequently, the government has found itself more frequently reimbursing pharmacies for purchasing drugs above standard costs, with price concessions soaring from 20 instances per month before 2016 to a peak of 199 per month in late 2022.
僅在 2023 年，就有 1,643 次警告，而 2020 年爲 648 次。因此，政府發現自己更頻繁地向藥房報銷購買高於標準成本的藥品，價格優惠從2016年之前的每月20次飆升至2022年底的每月199次的峯值。
Citing Mark Dayan, the Brexit program lead at the Nuffield Trust, the Financial Times highlighted that the challenges extend beyond Brexit, with global issues such as disrupted import chains from Asia due to Covid-19 exacerbating the situation.
《金融時報》援引納菲爾德信託基金脫歐項目負責人馬克·達揚的話強調，挑戰不僅限於英國退歐，諸如Covid-19導致亞洲進口鏈中斷等全球問題加劇了局勢。
Exiting the EU has compounded these issues, causing disruptions in the smooth flow of products across borders and potentially limiting the availability of alternative medicines in the long run.
退出歐盟加劇了這些問題，導致產品的順暢跨境流動中斷，從長遠來看，可能會限制替代藥物的供應。
The report underscores how Brexit has intensified vulnerabilities in global and UK-specific drug supply chains.
該報告強調了英國脫歐如何加劇了全球和英國特有藥物供應鏈的脆弱性。
Customs checks at borders and increased regulations for manufacturers, including those related to the UK's departure from the European Medicines Agency, have further complicated matters.
邊境海關檢查和對製造商的監管，包括與英國退出歐洲藥品管理局有關的監管，使問題進一步複雜化。
Some companies have even opted to exclude the UK from their supply chains.
一些公司甚至選擇將英國排除在供應鏈之外。
In addition to Brexit-related challenges, the UK's Medicines and Healthcare Regulatory Agency (MHRA) has struggled to approve drugs at the same pace as the EU, hindering the entry of generic medicines into the UK market.
除了與英國脫歐相關的挑戰外，英國藥品和醫療保健監管局（MHRA）一直難以以與歐盟相同的速度批准藥物，這阻礙了仿製藥進入英國市場。
Surges in demand for certain drugs, coupled with UK pricing policies, have further strained supplies in the country.
對某些藥品的需求激增，加上英國的定價政策，使該國的供應進一步緊張。
Despite efforts to address these issues, such as establishing a Critical Imports Council, concerns still need to be addressed about the UK's ability to mitigate future shortages without access to EU solidarity mechanisms.
儘管爲解決這些問題做出了努力，例如成立了關鍵進口委員會，但仍然需要解決人們對英國在沒有歐盟團結機制的情況下緩解未來短缺的能力的擔憂。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明： 該內容部分是在人工智能工具的幫助下製作的，並由Benzinga編輯審閱和發佈。
Image credit: Dall-E 3
圖片來源：Dall-E 3
譯文內容由第三人軟體翻譯。